Bladder · Mercurrey

Bladder Cancer Treatment in Majiwada, Kapurbawdi – Specialist Specialist Care at Mercurrey Hospital

₹1,000 consultationKapurbawdi, Majiwada

Bladder cancer treatment at Mercurrey Hospital Kapurbawdi Majiwada Thane – HRG Urology Cancer Lead
Cystoscopy · TURBT · BCG

Overview

The Ghodbunder Road corridor's corporate and professional population.Read moreShow less

IT workers, managers, executives in their 40s and 50s — includes individuals whose occupational histories, lifestyle factors, and health screening habits create a specific bladder cancer risk profile. Corporate health screenings increasingly include urine dipstick testing, and microscopic haematuria found on these screenings requires specialist follow-up that many corporate health departments do not facilitate. Mercurrey Hospital at Kapurbawdi junction provides the specialist bladder cancer assessment that Ghodbunder Road's health-aware professional community needs: cystoscopy, upper tract imaging, and where needed, TURBT and BCG therapy — all available at a location 10–15 minutes from most Ghodbunder Road residential communities.

What to know

Bladder Cancer Treatment at Mercurrey Hospital, Kapurbawdi

Bladder cancer most commonly presents as transitional cell carcinoma (TCC).Read moreShow less

Non-muscle-invasive bladder cancer (NMIBC) — Stages Ta, T1, CIS — is managed with TURBT (transurethral resection), intravesical BCG or chemotherapy, and flexible cystoscopy surveillance. Muscle-invasive bladder cancer (MIBC — T2+) requires radical cystectomy (laparoscopic where possible) or radical radiotherapy. Any episode of haematuria (blood in urine) in an adult requires urgent cystoscopy and upper tract imaging to exclude bladder cancer regardless of other possible explanations. Smoking is the most significant modifiable risk factor.

Corporate Health Screening Microscopic Haematuria — What to Do Next

Urine dipstick at corporate health screenings frequently detects microscopic haematuria (blood in the urine detectable only on chemical testing, not visible to the naked eye).Read moreShow less

Many corporate health providers note this finding without a clear follow-up pathway. Microscopic haematuria in a symptomatic adult, or in a high-risk individual (over 40, smoker, occupational exposure), requires specialist assessment. At Mercurrey Hospital, Dr. Godbole's team evaluates microscopic haematuria in the full clinical context — determining whether flexible cystoscopy and CT urography are indicated or whether the finding is likely to be benign (medication-related, strenuous exercise-related, or from a urological condition other than cancer).

Upper Tract Urothelial Cancer — An Under-Recognised Risk in Thane

Bladder cancer and upper tract urothelial cancer (UTUC) — cancers of the renal pelvis and ureter — share the same carcinogens and risk factors.Read moreShow less

A proportion of patients who present with haematuria at Mercurrey Hospital have an upper tract source rather than a bladder source for their bleeding. CT urography — which images the entire urothelial tract from kidney to bladder — is essential for identifying upper tract tumours that flexible cystoscopy alone would miss. Dr. Godbole's haematuria investigation protocol at Mercurrey Hospital includes CT urography alongside cystoscopy for this reason.

Travel and Parking Guide – Mercurrey Hospital, Kapurbawdi

High Street Mall Junction, Samata Nagar, Kapurbawdi, Majiwada 400607.Read moreShow less

From Hiranandani Estate: 10–12 minutes via Ghodbunder Road. From Manpada: 15 minutes. From Brahmand: 20 minutes. Auto-rickshaws know the junction as "Kapurbawdi High Street Mall." Street parking available.

Why Mercurrey

Ghodbunder Road professionals choose Mercurrey Hospital because the Kapurbawdi location is 10–20 minutes from their homes.Read moreShow less

Making the cystoscopy, CT imaging, and follow-up appointments that bladder cancer investigation requires practically manageable around demanding work schedules.

Dr. Godbole's haematuria investigation protocol at this location includes CT urography to exclude upper tract urothelial cancer.Read moreShow less

An investigation that many general urology services in Thane do not perform routinely alongside cystoscopy.

Microscopic haematuria found on corporate health screening receives specialist contextual assessment at Mercurrey Hospital.Read moreShow less

Determining whether full investigation is indicated, rather than leaving patients with an unexplained finding and no follow-up plan.

Nearby areas

MajiwadaKapurbawdiGhodbunder RoadManpadaHiranandani Estate

Mercurrey Hospital serves bladder cancer patients from Majiwada, Kapurbawdi, Ghodbunder Road, Manpada, Hiranandani Estate, Brahmand, Owale, Kolshet, and Pokhran Road.Read moreShow less

Patients from Mira Road and Bhayander also attend this clinic as the closest Cancer Lead urology option.

Questions

My corporate health check urine test showed 'blood in urine' — is this bladder cancer?

Microscopic haematuria on a dipstick test is not specific to bladder cancer — it can be caused by UTI, kidney stones, vigorous exercise, BPH, or anticoagulant medications. However, in a symptomatic adult over 40 or a high-risk individual, it requires specialist assessment to exclude bladder and kidney cancer. Dr. Godbole's team at Mercurrey Hospital evaluates microscopic haematuria in full clinical context — determining whether cystoscopy and CT urography are indicated for your specific risk profile.

What is CT urography and why is it done alongside cystoscopy for haematuria?

CT urography is a CT scan with IV contrast specifically optimised to image the entire urothelial tract — kidneys, ureters, and bladder. It identifies upper tract tumours (renal pelvis and ureteral cancers) that would be missed by cystoscopy, as cystoscopy only visualises the bladder interior. The combination of flexible cystoscopy (bladder) and CT urography (upper tract) provides a complete haematuria investigation covering all potential urothelial cancer sites.

I work in IT — does my occupation affect my bladder cancer risk?

Standard office-based IT work does not carry elevated bladder cancer risk. However, if your work has involved exposure to industrial chemicals — aromatic amines in printing, dye, leather, or rubber manufacturing — this does carry elevated risk. Additionally, the sedentary working pattern common in IT roles increases the time urine sits in the bladder, theoretically increasing carcinogen contact time, though this is a minor factor compared to smoking. The most significant action any IT professional can take to reduce bladder cancer risk is smoking cessation.

Is bladder cancer curable if treated early at Mercurrey Hospital?

Yes. Non-muscle-invasive bladder cancer (Stage Ta and T1) treated with complete TURBT followed by BCG therapy has an long-term prognosis. Low-grade Ta cancer has a very low risk of progression to muscle-invasive disease; high-grade T1 cancer with BCG maintenance therapy has progression rates of 10–20% over 5 years with appropriate management. Stage 1 bladder cancer does not require bladder removal — it is managed with cystoscopic surveillance and intravesical therapy.

How does BCG therapy work and is it available at Mercurrey Hospital?

BCG (Bacillus Calmette-Guérin) is instilled directly into the bladder through a urinary catheter and left for 1–2 hours before voiding. The immune response it triggers attacks remaining tumour cells and creates an immune memory that reduces recurrence. BCG is given once weekly for 6 weeks (induction) and then as maintenance therapy (3 weekly instillations at 3, 6, 12, 18, 24, 30, and 36 months for intermediate and high-risk NMIBC). BCG therapy is coordinated by HRG Urology at Mercurrey Hospital as part of the complete bladder cancer management pathway.

Bladder

More at Mercurrey

Mercurrey Hospital · Kapurbawdi, Majiwada

Book a consultation

₹1,000 consultation. All professional fees go to charity. Calls answered after 2:00 PM IST.

Factual information about Dr. Harshawardhan Godbole's qualifications, clinics, fees and services, in line with the NMC Guidelines on Ethical Advertising and Public Communication (R-13014/01/2024-Ethics). Regulatory information

Call +91 88280 71522